Research report covers the Facial Injectable Market Forecasts, 2016 - 2020

Growing popularity of minimally invasive cosmetic surgeries and increasing disposable income has led to substantial growth in the overall cosmetic procedures market. Facial injectable are generally used for skin rejuvenation, reduction or elimination of dark spots and wrinkles, and lip enhancement. The market for facial injectables has been broadly segmented as follows:

Botulinum Toxin
Hyaluronic Acid
Collagen
Polymers and Particles
Dermal Fillers

Click For Request TOC@ http://www.sa-brc.com/Global-Facial-Injectable-Market-Assessment--Forecast-2016---2020/upcomingdetail43

Hyaluronic acid and poly-L-lactic acid (PLLA) are commonly used long lasting facial injectable products which are reported to last from 10 months to 15 months depending on injection site. Restylane (Gladrma) and Juvederm (Allergan) are most popular hyaluronic acid facial injectable brands worldwide. Botulinum toxin marketed under brand names Botox (Allergan) and Dysport (Gladerma) is also one of the long standing products in the market. According to The American Academy of Facial Cosmetics, Botulinum toxin procedures for facial rejuvenation are increasing at a rate of about 4.5% annually in the U.S. Furthermore, statistics published by the American Society of Plastic Surgeons states that between 2013 and 2014, hyaluronic acid (HA) filler treatments had increased by over 8%.

The global facial injectables market is highly competitive, and dominated by few global players. U.S. leads the overall facial injectable market; however the market is rapidly growing in South-East Asian countries owing to increasing trend for medical tourism. In the recent past there has been a surge of counterfeit products circulating in the Asian market. In 2013, ShanghaiDaily published that some patients had approached physicians with complaints of swollen face after using Botox products purchased online at substantially lower costs. In China, Hongli (Lanzhou Institute of Biological Products) and Botox (Allergan) are the only approved botulinum toxin brands. To tap lucrative market opportunity in the facial injectables market, various fake treatment centers have also emerged in this region.

For More Research Reports@ http://www.sa-brc.com/Medical-Devices/upcoming1

In October 2013, Allergan announced that Juvederm Voluma XC was approved in the U.S. as the first and only dermal filler for deep injection to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. Cosmetic Botox accounted for 15% share in the company’s revenue in 2013. In 2014, Gladerma (Nestlé S.A.) announced that it entered into an agreement with Valeant Pharmaceuticals International, Inc. to gain full commercialization rights for Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada. These events have changed the global facial injectable market place. Zyderm, Sculptra, Captique, Hylaform, Artefill are other brands competing in the market.

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.